Prostate Cancer – Mission statement

Our Mission

The aim is to provide the best prostate cancer care in the world at all points of the journey of patients, be it at screening, diagnosis, treatment or through support in their daily life.

We embrace quality-focussed team working to improve outcomes for patients.

Patient care, innovation and research go seamlessly hand-in-hand to lead in all areas of Prostate Cancer.


Cambridge – A leading centre in Prostate Cancer care and research.

Clinical care

Prostate cancer services played a key role in the growth of the Urology department at Addenbrooke’s Hospital. We are one of the international leaders in MRI-based diagnostics for Prostate Cancer and have one of the largest UK robotic prostatectomy programmes with published outcome data. Oncological treatments are provided to the highest standards.

Per year we perform

  • over 300 MRI-based diagnostic procedures (the highest number in the UK)
  • over 500 radiation treatments
  • over 200 robotic prostatectomies with continuing increase in demand (NICE guidance: a centre should do no less than 150/year)
  • over 100 brachytherapy procedures
  • we offer safe active surveillance with PSA, MRI and targeted biopsies
  • 200-300 treatments with hormone- and chemotherapy.

95% of prostate cancer patients treated at CUH live for at least 5 years (UK average 83%; Europe “best” countries overall average 85%).  10 and 20 year survival rates are equally world-leading.


Members of the prostate team have formed a translational Prostate Cancer research collaborative to coordinate their activities in Cambridge.

The following institutions are involved:

  • Departments of Oncology, Radiology and the Academic Urology Group at the University of Cambridge
  • Departments of Pathology, Radiology, Oncology and Urology at Addenbrookes Hospital
  • Cambridge Urology Bio-repository – Cambridge Cancer Centre
  • Associations with the Cambridge Institute, the MRC Hutchison and the Sanger Institute

The bio-repository is one of the most comprehensive, with state-of-the-art facilities for analysis and providing information to the International Cancer Genome Consortium.

The cookie setting on this website is set to ‘allow cookies’ to give you the very best experience.

If you continue without changing this setting, you consent to this - but if you want, you can change your setting at any time using the ‘change cookie setting’ link at the bottom of this page.

Cookie Setting

Our Cookies

Cookie NamePurpose
eu_ask This is used to store the cookie setting you set in the form above.
If you choose 'Do Not Allow Cookies' we will need to store this information as a cookie with the value N.
If you choose 'Allow Cookies' or do not make a choice, we will store this information as a cookie with the value Y.

The value is kept for one year.

3rd Party Cookies

Cookie NamePurpose
Google Analytics This website uses Google Analytics, a web analytics service provided by Google, Inc.
Google Analytics sets a cookie in order to evaluate your use of the website and compile reports for us on activity on the website.
Google stores the information collected by the cookie on servers in the United States.
Google may also transfer this information to third parties where required to do so by law,
or where such third parties process the information on Google's behalf.
Google will not associate your IP address with any other data held by Google
By using this website, you consent to the processing of data about you by Google in the manner and for the purposes set out above.

How to reject or delete this cookie